Secukinumab treatment in spondyloarthritis: Retention rate and effectiveness data at 12 months – data from the Romanian Registry of Rheumatic Diseases

• Published in: Revista română de reumatologie 2020-12, Vol.29 (4), p.151-156
• Main Authors: Mogosan, Corina, Ionescu, Ruxandra, Rednic, Simona, Parvu, Magda, Rezus, Elena, Codreanu, Catalin
• Format: Article
• Language: English
• Subjects: effectiveness; registry; retention rate; secukinumab
• ISSN: 1843-0791; 2069-6086
• DOI: 10.37897/RJR.2020.4.2

Background. Registries data are important contributors to complement information provided by randomized controlled trial reports in terms of effectiveness and safety evaluation for anti-rheumatic drugs used in clinical practice. Objectives. We aimed to estimate the 12 month secukinumab retention rate and effectiveness in patients with axial spondyloarthritis. Data from the Romanian Registry of Rheumatic Diseaases (RRBR, in Romanian) were collected for all patients who received at least one course of secukinumab. The retention rate was calculated using Kaplan-Meier method with log-rank test. Effectiveness was assessed at 6-month and at 12-month for inactive disease and for low disease activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI < 2 and BASDAI < 4) and Ankylosing Spondylitis Disease Activity Score (ASDAS < 1.3 and ASDAS < 2.1). Results. The study included 616 patients with axial spondyloarthritis who received secukinumab. 226 patients were naïve to biologic treatments; 220 patients had one prior bDMARD; 170 patients used two or more bDMARDs. The overall 6-months and 12-months secukinumab retention rates were 68%/49% with significant differences in favour of biologic naïve patients: bDMARD-naïve: 78%/58%, 1 prior bDMARD: 63%/45%, ≥ 2 prior bDMARDs: 61%/41%. The 6-month and 12-month results for effectiveness: overall BASDAI < 2: 54%/66%; overall BASDAI < 4: 91%/97%; overall ASDAS < 1.3: 14%/19%; overall ASDAS < 2.1: 53%/73%. The number of previous bDMARDs had an impact on effectiveness, with more responders being observed in the biologic naïve group. Conclusions. Our results show that the best retention rate for secukinumab treatment, as well as efficacy, is attained for the bio-naive treatment group. The main reason for discontinuation of secukinumab treatment is secondary loss of efficacy